Original Research Paper

Volume - 12 | Issue - 09 | September - 2022 | PRINT ISSN No. 2249 - 555X | DOI : 10.36106/ijar

Biochemistry

EVALUATION OF GLUCAGONE LIKE PEPTIDE-1(GLP-1) LEVEL IN IMPAIRED GLUCOSE REGULATION

Ajay Jain	Assistant Professor, Department Of Biochemistry, JLN Medical College,Ajmer, Rajasthan, India- 305001
Sandeep Sharma*	Post Graduate Resident, Department Of Biochemistry, JLN Medical College,Ajmer, Rajasthan, India- 305001. *Corresponding Author
Deepa Thadani	Sr. Professor, Department Of Biochemistry, JLN Medical College,Ajmer, Rajasthan, India- 305001.
Sarla Mahawar	Professor & Head, Department Of Biochemistry, JLN Medical College,Ajmer, Rajasthan, India- 305001.

ABSTRACT **Background:** Between diabetes and normal glucose homeostasis lies a metabolic condition referred to as impaired glucose regulation. Patients with type 2 diabetes have a reduced incretin Harmon specially GLP-1. **Aim:** To determine if a low GLP-1 response may be a predictor of adult-onset prediabetes by evaluating the relationship between the incretin hormone GLP-1 and the prediabetic subtypes of impaired fasting glucose (IFG), impaired glucose tolerance (IGT), and combined IFG/IGT. **Method & Material:** Present study is a cross-sectional study,was conducted in the Department of Biochemistry,J.L.N. Medical college,Ajmer(Raj.).186 subjects were enrolled in three groups, 62 with DM2,62 prediabetes state and 62 norml subjects of first-degree relatives of diabetic group. After clinical examination, blood samples were taken to measure fasting blood glucose, HbA1c, lipids, insulin, and GLP-1 concentrations. **Result:** The average blood levels of GLP-1 in all groups were lower than the normal range (20 ± 6.4 ng/ml). **Conclusion:** This study found raised, unaffected, and lowered GLP-1 levels as well as IFG/IGT found unaltered or decreased GLP-1 levels for early detection of prediabetic and diabetic patients in the general population to minimise the morbidity and mortality linked to impaired glucose control.

KEYWORDS : Incretin,Glucagone like pepdite-1(GLP-1), Impaired fasting glucose (IFG),), Impaired glucose tolerance (IGT), and combined IFG/IGT, Impaired glucose regulation,Type 2 DM,Prediabetes

INTRODUCTION

World Health Organization (WHO) has projected the maximum increase in diabetes would occur in India. International Diabetes Federation (IDF) estimates the total number of diabetic subjects to be around 40.9 million in India and this is further set to rise to 69.9 million by the year 2025. To gain a more profound insight into the pathogenesis of type 2 diabetes, the initial defects responsible for fasting and post-prandial glucose deregulation need to be elucidated in individuals with impaired fasting glucose (IFG) and impaired glucose tolerance (IGT).

Between diabetes and normal glucose homeostasis lies a metabolic condition referred to as **impaired glucose regulation**. Between normal glucose tolerance and type 2 diabetes mellitus, it is regarded as an at-risk condition.Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance(IGT) are indicators of pre-diabetes Oral glucose tolerance testing can identify IGT. IFG and IGT are both risk factors for Type 2 diabetes, and the risk is increased when they co-occur[1]. Pre diabetes is the main contributor to Type 2 diabetes risk [2]. Pre-diabetes is a condition that has a high chance of developing diabetes,with an annual conversion rate of 8–10% [3].

Given the high prevalence of Diabetes Mellitus, it's critical to determine the variables that might influence the disease's course and result in pathological alterations in the body [4]. Following meal consumption, there is an increase in the production of certain gut peptides that operate on distant target locations to facilitate the effective uptake and storage of energy. These peptide hormones are produced by specific enteroendocrine cells that are found in the stomach, small intestine, and large intestine epithelium and are released at low baseline levels during a fast. Gut hormones cause neuronal circuits in the liver, muscles, adipose tissue, and islets of Langerhans in the pancreas to become active.[5]

When glucose is orally ingested, it elicits a much greater insulin response (two- to threefold) than if glucose is intravenously injected to give the same blood glucose level. This phenomenon is called the incretin effect and is due to the secretion of glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) which increases the glucose-induced insulin secretion [6]. Reduced endogenous synthesis of glucose from hepatic sources results from incretin activity, which promotes the absorption of glucose by muscle tissue and the liver while concurrently reducing glucagon release by the islet cells. In preclinical investigations, GIP and GLP1 both raise cAMP levels, which results in an increase in cell mass and resistance to apoptosis [7]. Together, GLP-1 and GIP have been shown to fully explain the incretin effect and are thought to be physiologically active compounds that contribute to the glucose-dependent release of insulin.

GLP-1 is a gastrointestinal hormone secreted from the L cells of the distal part of the small intestine. It is derived from a large proglucagon (i.e., glucagon precursor) that also encodes for glucagon. **GIP** is a 42-chain amino acid peptide secreted by the lymphocyte K cells, which are located within the intestinal epithelium of the proximal duodenum and are regulated predominantly by fat consumption. Receptors for GLP-1 and GIP can be found in a number of organs, including brain, duodenum, kidneys, liver, lungs, pancreas and stomach.[6]

Various Studies have showed changes in Incretin, GLP-1 levels in IFG, IGT and Type 2 diabetes mellitus, but data showing association of these parameters levels in impaired glucose regulation are not fully elucidated, so further research is required. Therefore, the present study will be undertaken to determine the levels of Incretin, glucagon like peptide-1(GLP-1) in impaired glucose regulation(IFG+IGT) and newly diagnostic type 2 diabetes mellitus,also will assess the relation between the incretin hormone GLP-1 and the prediabetic state and investigate whether GLP-1 may be a predictor of prediabetes in adults. Moreover, it will assess reliability; sensitivity and high diagnostic accuracy of these parameters between healthy individuals and impaired glucose regulation .

MATERIALS AND METHODS

This study is a cross-sectional study, was conducted in the Department of Biochemistry, J.L.N.Medical college and Associated group of Hospitals, Ajmer(Raj.).124 cases of predaibetes,Diabetes Mellitus attending Medical OPD of J.L.N. Hospital were enrolled in three groups,62 newly diagnosed DM2 subjects (one year or less) were put into the first group.62 with fasting plasma glucose (FPG) concentration between 100 and 126 mg/dl confirmed twice in repeated measurements or those with impaired glucose tolerance (IGT)defined by ADA criteria (Two-hour plasma glucose 140–200 mg/dL during a75 gr oral anhydrous glucose tolerance test)were considered as prediabetes group 2.For control group 62 Offspring of patients with DM2 who were more than twenty years old were invited and checked for their FPG and those who were normoglycemic (FPG <100 mg/dl) were entered in 3rd group.

This study was approved by institutional ethical committee. All the participants were informed about the aims of study and written consent were obtained from all of them.

Inclusion Criteria for study group

Age group between 20-50 year of both sex diagnosed as DM2,predaibetec and healthy individuals.

Exclusion Criteria for study group

- Patient with history of using oral hypoglycemic agents or insulin.
- Patient with history of medications that affect blood lipids or insulin levels, supplements and appetite altering drugs.
- Case of Heart failure
- Hepatic and Renal Failure cases
- Acute and Chronic Inflammatory dieases.

Venus Blood samples were taken after at least 12 hours of fasting in all the participants. A standard 75g glucose OGTT was conducted for each subject after an overnight fasting (longer than twelve hours). Blood samples were collected only at the 0 and 2 hours following OGTT, as most of the subjects were unwilling to accept the blood collections at 15, 30 and 60 min during their OGTTs. The blood used for the GLP-1 determinations was collected in tubes without any aprotinin, DPP-IV inhibitor or anticoagulant. After centrifugation at 4 ℃, all serum samples were stored at -80 ℃ till they were analyzed.Plasma glucose was measured by the glucose-peroxidase colorimetric enzymatic method with a sensitivity of 5 mg/dl . HbA1c Serum Cholesterol and Triglyceride and High density lipoprotein cholesterol (HDL-C) levels were measured with AU-680 (Backman) fully autoanalyzer, fasting serum Insulin level were measured with electrochemiluminescence immunoassay(ECLIA) using commertial kits (Roche, German), with sensitivity of 0.75 µiu/ml (normal range:0.7-25 µiu/ml). To calculate insulin resistance, HOMA-IR was used based on the formula of glucose × insulin/405 and values higher than 2.1 was considered insulin resistance[14].

A standard approach for the collection of blood samples was employed, including collection of blood samples, to get precise data on GLP-1 concentrations. Place a full blood sample in a centrifuge for 20 minutes at a speed of around 1000 g for 2 hours at room temperature or overnight at 2 to 8 °C. Take the supernatant and do the test right away. Serum GLP-1 was determined using the Elisa kit from Wuhan Fine Biotech Co., Ltd,china.These tests were done with long immunological reaction method (incubation 4 to 20 hours) to achieve maximum sensitivity of 0.188 ng / ml for GLP-1. Intra assay and inter assay CV of the kit to measure GLP-1 was <8% and <10% respectively.

Statistical analysis

All data were analyzed with SPSS-13 version. Descriptive statistics such as mean,median and standard deviation were used to describe the statistics. ANOVA was used to compare the groups for quantitative and chi-square test was used for qualitative variables. To assess the relationship between the variables simple and multivariate regression analysis were used.

RESULTS

186 eligible patients were assigned in 3 groups as follows: 62 subjects with diabetes mellitus type 2 in 1st group, 62 patients with IFG or IGT in 2nd group, and 62 participants with normoglycemic status in 3rd group.The mean age of the first group was 48.7 ± 12.6 years and in the second group was 52.6 ±13.2 years. Although no significant difference was found between diabetic and prediabetic patients for their age, normoglycemic subjects in the third group were significantly younger(31.4 ± 10.3, p < 0.0001). There were no significant differences within three groups by sex.Clinical and laboratory characteristics of the participants have been illustrated in Table 1.

Table -1 Anthroprometric Parameters of DM2,Prediabetic and control healthy subjects

	Group1 (Dm2) [N: 62]	Group 2 (prediabetic) [N: 62]	Group 3(control) [N: 62]	P-value
Age (years)	48.7 ± 12.6	52.6 ± 13.2	31.4 ± 10.3	0.00011
Weight (kg)	78.2 ± 18.2	73.7 ± 13.2	77.3 ± 14.1	0.521
BMI(kg/m2)	29.2 ± 5.4	27.8 ± 4.5	28.8 ± 4.3	0.548



In Table 2, there was significant difference for each parameter among the groups (P<0.05). Multiple comparisons results between the groups were as follows: [1]. FPG: NGT and isolated IGT groups < isolated IFG group < IFG+IGT group < NDDM group (P<0.005); [2]. 2hPG: NGT and isolated IFG groups < isolated IGT group < IFG+IGT group < NDDM group (P<0.005); [3]. Fasting insulin (FINS) concentrations: NGT group < isolated IFG, isolated IGT, IFG+IGT and NDDM groups (P<0.005); [4]. 2-hour insulin (2hINS) concentrations during the OGTT: NGT group < isolated IFG group < isolated IGT, IFG+IGT and NDDM groups (P<0.005); [5]. Total FGLP-1 levels: NGT, isolated IFG and isolated IGT groups > NDDM group (P<0.005), while isolated IGT group > IFG+IGT group > NDDM group (P<0.005); [6]. Total 2hGLP-1 levels: NGT, isolated IFG and IGT groups > IFG+IGT and NDDM groups (P<0.005); [7]. ΔGLP-1: NGT and isolated IFG groups > IFG+IGT and NDDM groups (P<0.005), while NGT group > isolated IGT group > IFG+IGT and NDDM groups (P<0.005).

Table 2. Comparisons of plasma glucose, serum insulin, total GLP-1 concentrations (at each time point) and ΔGLP-1 in different hyperglycemic conditions.

	NGT	Isolated IFG	Isolated IGT	IFG+IGT	NDDM	Overall p value
FPG (mmol/l)	4.6± 0.4	6.0± 0.3	4.8± 0.5	6.2± 0.36	7.4± 2.3	0.005
FINS (mU/l)	7.1± 2.9	9.0± 4.33	9.1± 4.2	11.0± 6.2	11.2± 9.4	0.005
Total FGLP-1(ng/ml)	23.9± 11.2	23.1± 11.7	26.4± 8.1	20.1± 11.3	10.6± 8.1	0.005
2hPG (mmol/l)	5.4± 1.3	5.8± 1.3	8.4± 0.8	9.2± 0.9	14.9± 4.3	0.005
2hINS(mU/l)	32.6±26.2	44.5±38.1	72.1±40.1	68.8±45.2	69.42±60.3	0.005
Total 2hGLP-1(ng/ml)	35.3±15.0	34.1±15.3	35.6±13.2	22.4±16.2	16.49±14.1	0.005
ΔGLP-1(ng/ml)	15.8±10.0	10.2±9.2	9.7±10.5	2.7±6.1	4.0±6.4	0.005

Although the total FGLP-1 levels were not significantly different among NGT, isolated IFG and IGT groups, they reduced obviously in the IFG+IGT and NDDM groups (P<0.005), especially in the NDDM group. After the 75g glucose load, the total 2hGLP-1 concentrations were increased in all groups. No statistical significance was found among the NGT, iso-lated IFG and IGT groups (P>0.005).

However, the 2hGLP-1 levels in the IFG+IGT and NDDM groups were lower than that in the previous three groups (P<0.005). There was no significant disparity of ΔGLP-1 between the NGT and isolated IFG groups (P>0.005). But compared to them, the GLP-1 responses to the OGTT decreased significantly in the isolated IGT, IFG+IGT and NDDM groups (P<0.005). Moreo-ver, there was no significant difference for ΔGLP-1 in the IFG+IGT and NDDM groups (P>0.005), however, it was manifestly lower than that in isolated IGT group (P<0.005).

DISCUSSION

Prediabetic individuals (IFG and IGT) have a higher risk of both cardiovascular disease and type 2 diabetes [7,8,9]. Based on fasting and two-hour glucose levels, the classifications of IFG and IGT describe categories of glucose tolerance that may have various etiologies, metabolic profiles, and prognostic significance.

Zhang et al.(11) found a reduced fasting GLP-1 when comparing IFG/IGT with i-IGT.When comparing IFG/IGT with both NGT, i-IFG and i-IGT, they found a reduced 2-hour GLP-1 and a reduced

ΔGLP-1.Potential Mechanisms for the Eventually Reduced GLP-1 Response in Prediabetes. Rask et al. [36] have found a reduced GLP-1 secretion in response to a mixed meal in nondiabetic men with insulin resistance. This suggests an association between insulin resistance and GLP-1 secretion.

It is thought that incretin effect determines about 50–70% of the postprandial insulin response. There is evidence that incretins' action is disturbed in type 2 diabetes mellitus (T2DM) – a condition which is levels and a reduced response towards both incretins– GLP-1 and GIP.(10)

According to Toft-Nielsen et al. (12), individuals with type 2 diabetes mellitus did not have substantially lower fasting GLP-1 levels than those in the normal glucose tolerance (NGT) group. The area under the curve (AUC), the postprandial GLP-1 levels, and the GLP-1 increments were all considerably lower in the 4-hour mixed meal tolerance tests as compared to the NGT group. And those levels were between the two groups for persons with impaired glucose tolerance (IGT) (the NGT and T2DM groups).

Laakso M et al. (13) discovered that all three groups with impaired glucose tolerance saw decreased secretion of GLP-1 but not GIP. GLP-1 levels were reduced in both IFG and IGT participants, and since these states have different early insulin responses to glucose, it can be inferred that this abnormality is unlikely to be the cause of the glucose intolerance. However, reduced incretin effect and reduced GLP-1 levels have previously been reported in type 2 diabetic participants as well as in those with IGT.

According to Fang Zhang et al. (11), those with IFG+IGT and NDDM exhibited considerable GLP-1 secretion impairment and were experiencing more severe hyperglycemia than people with pure IFG or IGT. Additionally, isolated IGT participants had lower levels of 2hGLP-1 (after oral glucose stimulation), and those levels were considerably lower in those with IFG+IGT and NDDM. Additionally, while comparing IFG/IGT with i-IGT, a lower fasting GLP-1 was discovered. They discovered a reduced 2-hour GLP-1 and a reduced GLP-1 when comparing IFG/IGT with both NGT, i-IFG, and i-IGT.

D.Nathanson et al. (14) interpret that impaired GLP-1 secretion is associated with IGT and Type-2 diabetes mellitus. Agus Lastya et al. (15) shows that Both FGLP-1 and 1hGLP-1 levels were lower in subjects with Type-2 diabetes mellitus than in subjects with NGT. Low level of GLP-1 was an important risk factor of Type-2 diabetes mellitus. A.K. Singh et al. (16)suggests that the GLP-1 level progressively decreases with increasing duration of dysglycemia, meta-analysis of various studies suggests no significant changes in GLP-1 level. Nevertheless, the final conclusion can only be derived from prospective or longitudinal studies, which will measure GLP-1 level along the entire course of diabetes starting from normoglycemia to IGT to frank diabetes and its further course over the years

CONCLUSION

This study found raised, unaffected, and lowered GLP-1 levels as well as IFG/IGT found unaltered or decreased GLP-1 levels for early detection of prediabetic and diabetic patients in the general population to minimise the morbidity and mortality linked to impaired glucose control.

REFERENCES

1. American Diabetes Association. 2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes-2020. Diabetes Care 2020;43(1):S14–S31.
2. Kacker S, Saboo N, Jitender. Pre diabetes: Pathogenesis and Adverse Outcome. Int J Med Res Prof. 2018; 4(2):1-6.
3. Fujiati II, Damanik HA, Bachtiar A, Nurdin AA, Ward P. Development and validation of pre diabetes risk score for predicting pre diabetes among Indonesian adults in primary care: Cross-sectional diagnostic study. Interv Med Appl Sci. 2017; 9(2):76-85.
4. Edmann J, Lipple F, Wagenpfeil S. Differential association of basal and postprandial plasma ghrelin with leptin, insulin, and type 2 diabetes. Diabetes .2005; 55:8–1371.
5. Drucker D.J. Glucagon like peptides: regulators of cell proliferation, differentiation, and apoptosis. Mol. Endocrinol. 2003;17:161–171.
6. Faerch K, S. S. Torekov, D. Vistisen. GLP-1 response to oral glucose is reduced in prediabetes, screen-detected type-2 diabetes, and obesity and influenced by sex:the ADDITIONPRO study. Diabetes. 2015; 64(7):2513–2525.
7. Lillioja S, Mott DM, Spraul M et al (1993) Insulin resistance and insulisecretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N Engl J Med,329:1988–1992.
8. Haffner SM, Miettinen H, Gaskill SP, Stern MP (1995) Decreased insulin secretion and increased insulin resistance are independently related to the 7-year risk of NIDDM in Mexican-Americans.Diabetes 44:1386–1391.
9. Laakso M (2005) Prevention of type 2 diabetes. Curr Mol Med,5:365–374.
10. Visboll T, Holst JJ. Incretins, insulin secretion and type 2 diabetes [review]. Diabetologia 2004; 47:357-66.
11. Zhang F, Tang X, Cao H, Lü Q, Li N, Liu Y, Zhang X, Zhang Y, Cao M, Wan J, An Z, Tong N. Impaired secretion of total glucagon-like peptide-1 in people with impaired fasting glucose combined impaired glucose tolerance. Internat J Med Scien. 2012; 9:574–581.
12. Toft-Nielsen BM, Damholt BM, Madsbad S. Determinants of the Impaired Secretion of Glucagon-Like Peptide-1 in Type 2 Diabetic patients. J Clin Endocrinol Metab. 2001; 86:717-72.
13. Laakso M, Zilinskaite J, Hansen T. Insulin sensitivity, insulin release and glucagon-like peptide-1 levels in persons with impaired fasting glucose and/or impaired glucose tolerance in the EUGENE2 study. Diabetologia. 2008; 1:502-511.
14. Nathanson D, Zethelius B, Berne C. Reduced plasma levels of glucagon-like peptide-1 in elderly men are associated with impaired glucose tolerance but not with coronary heart disease. Diabetologia. 2010; 53:277-280.
15. Agus Lastya, Made Ratna Saraswati and Ketut Suastika. The low level of glucagon-like peptide-1 (glp-1) is a risk factor of type 2 diabetes mellitus. BMC Research Notes. 2014; 7:849.
16. A. K. Singh. Glucagon-like peptide 1 and dysglycemia: conflict in incretin science. Indian Journal of Endocrinology and Metabolism.2015; 19(1):182–187.